<p>Magi and Jurkat cells were treated with various therapeutic drugs (MF-Metformin (1 mM), Min-Minocycline (5 µg/ml and 10 µg/ml), Sim-Simvastatin (2.5 µM), and AZT (100 µM), S.Sali-Sodium salicylate (1 mM) either alone or in combination with bryostatin for 48 and 72 h and cell survival was determined using WST8/CCK8 cytotoxicity assay. (<b>A</b>) Survival of Magi cells after treatment with bryostatin and other drugs, (<b>B</b>) bryostatin in combination with other drugs. (<b>C</b>) Jurkat cell survival after treatment with bryostatin (25 ng/ml) and other drugs, (<b>D</b>) bryostatin in combination with other drugs. Each treatment was done in triplicate. (n = 2).</p
ABSTRACT: Bryostatin 1, in clinical trials or preclinical development for cancer, Alzheimer’s diseas...
HIV latency in resting CD4+ T cell represents a key barrier preventing cure of the infection with an...
Bryostatin 1 interferes with protein kinase C (PKC) signaling which is involved in the activation of...
<p>Magi cells (CD4<sup>+</sup>/CCR5<sup>+</sup>) were infected with 100 ng/ml p24 equivalent HIV rec...
HIV's ability to establish long-lived latent infection is mainly due to transcriptional silencing in...
<p>Jurkat cells were pretreated either with bryostatin or other drugs, infected with 50 ng/ml p24 eq...
<p>(<b>A</b>) THP-p89 cells were treated with bryostatin (25 ng/ml) for different durations and fluo...
<p>(<b>A</b> and <b>B</b>) THP-p89 cells were pretreated with bryostatin either alone or with broad ...
Bryostatin is a unique lead in the development of potentially transformative therapies for cancer, A...
Bryostatin 1 is a novel antitumour agent derived from Bugula neritina of the marine phylum Ectoproc...
The present study was aimed to investigate the effect of bryostatin I on the expression of synuclein...
<p>(<b>A</b>) Jurkat cells were treated either with bryostatin (25 nM) or left untreated for 0 to 48...
<p>The T-lymphoid J-Lat 9.2 (panel <b>A</b>) and monocytic THP89GFP (panel <b>B</b>) cell lines harb...
The ability of HIV to establish a long-lived latent infection within resting CD4+ T cells leads to p...
ABSTRACT: Bryostatin 1 is in clinical trials for the treatment of cancer and Alzheimer’s disease and...
ABSTRACT: Bryostatin 1, in clinical trials or preclinical development for cancer, Alzheimer’s diseas...
HIV latency in resting CD4+ T cell represents a key barrier preventing cure of the infection with an...
Bryostatin 1 interferes with protein kinase C (PKC) signaling which is involved in the activation of...
<p>Magi cells (CD4<sup>+</sup>/CCR5<sup>+</sup>) were infected with 100 ng/ml p24 equivalent HIV rec...
HIV's ability to establish long-lived latent infection is mainly due to transcriptional silencing in...
<p>Jurkat cells were pretreated either with bryostatin or other drugs, infected with 50 ng/ml p24 eq...
<p>(<b>A</b>) THP-p89 cells were treated with bryostatin (25 ng/ml) for different durations and fluo...
<p>(<b>A</b> and <b>B</b>) THP-p89 cells were pretreated with bryostatin either alone or with broad ...
Bryostatin is a unique lead in the development of potentially transformative therapies for cancer, A...
Bryostatin 1 is a novel antitumour agent derived from Bugula neritina of the marine phylum Ectoproc...
The present study was aimed to investigate the effect of bryostatin I on the expression of synuclein...
<p>(<b>A</b>) Jurkat cells were treated either with bryostatin (25 nM) or left untreated for 0 to 48...
<p>The T-lymphoid J-Lat 9.2 (panel <b>A</b>) and monocytic THP89GFP (panel <b>B</b>) cell lines harb...
The ability of HIV to establish a long-lived latent infection within resting CD4+ T cells leads to p...
ABSTRACT: Bryostatin 1 is in clinical trials for the treatment of cancer and Alzheimer’s disease and...
ABSTRACT: Bryostatin 1, in clinical trials or preclinical development for cancer, Alzheimer’s diseas...
HIV latency in resting CD4+ T cell represents a key barrier preventing cure of the infection with an...
Bryostatin 1 interferes with protein kinase C (PKC) signaling which is involved in the activation of...